Investor presentationSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 16 Sep - One-on-one virtual analyst/investor meet held on September 16, 2026; no presentation and no UPSI shared.
Source: Bse
NGL Fine-Chem Limited (NGLFINE)
Small CapPharma stocks · Small cap · NSE
NGL Fine-Chem Limited operates in API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 05:57 pm ISTDetails
Quote21 Oct, 05:57 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result12 Aug, 07:02 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
75BullishSMA20 +4.2% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 59
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
NGLFINED candles · FIT view+13.2%Latest close ₹2623.40 on 2026-10-21
Bar
-4.9%
RSI
35
MACD hist
-27.94
52W pos
58%
2026-10-21O ₹2758.90H ₹2800.00L ₹2601.00C ₹2623.40Vol 3,888 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
NGLFINENifty PharmaNifty 500
- NGLFINE
- -19.0%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -12.5 pp
Chart stats
21 Oct 2026- From 52W high
- -27.2%
- 52W range position
- 58%
- ATR (14)
- 5.2%
- Volume vs 20D
- 0.48x
- Avg traded value
- ₹2.4 Cr
- 20D price channel
- ₹2,601 - ₹3,250.3
₹3,602
₹1,271 - ₹3,602
₹137.4
Latest completed session
20-session average
48.9% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST38
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent90
Revenue +33.6% · PAT +100.0% YoY
Technical
Bullish75
Price trend and sector-relative-strength timing.
Valuation
Legacy model-315.4%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence76
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 90/100Rev +34% YoY · PAT +100% YoY · margin expansion · operating leverage
Filed 12 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹139 Cr | +33.6% | -6.7% |
| EBITDA | ₹23 Cr | +109.1% | +9.5% |
| Operating margin | 17.0% | +600 bps | +300 bps |
| PAT | ₹18 Cr | +100.0% | +38.5% |
| PAT margin | 12.9% | +430 bps | +423 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 32.30
- P/B
- 5.61
- EV/EBITDA
- 18.76
- Market Cap
- 1847.00Cr
Profitability
- ROE
- 17.40%
- ROCE
- 18.60%
- ROA
- 10.46%
- Dividend Y
- 0.06%
Growth (CAGR)
- Revenue 5Y
- 14.00%
- EPS 5Y
- -1.00%
- Revenue 3Y
- 22.00%
- EPS 3Y
- 37.00%
Balance Sheet
- Debt/Equity
- 0.37
- Interest Coverage
- 21.00×
- Altman Z
- 7.68
- Book Value
- 533.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 2/5
- OCF
- 43.00 Cr
- EPS TTM
- 92.61
Shareholding
- Promoter Hold
- 72.49%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 74%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 139-6.7% vs prev
Net Profit
₹ CrLatest: 18.0+38.5% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 35. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~4.0% over last month) — short-term momentum positive.
- RSI(14) at 35 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 27% off 52W high · 106% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
88
RS percentile
Stage 1 Base / Transition
1M return
-4.0%
3M return
-19.0%
6M return
+14.8%
1Y return
+72.4%
RS 1D
-2
RS 20D
0
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is within 5.2% of the 30-week proxy.
- The 30-week proxy changed +3.0% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 193.01-4.51%
RS vs Nifty 500193
Valuation & peers
U-Score 38 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 38 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation2/30
Growth6/25
Quality13/20
Balance Sheet10/15
Cash Flow2/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
38
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
38/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 10/15 to the score.
- Quality contributes 13/20 to the score.
Main drags
- Fair-value margin of safety is negative at -315.4%.
- Valuation is weaker at 2/30; verify the latest quarterly trend.
- Cash flow is weaker at 2/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
32.3
PB
5.6
EV/EBITDA
18.8
ROE
17.4%
ROCE
18.6%
FCF Yield
—
Debt/Equity
0.4
MoS
-315.4%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
38
Previous: 38
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-315.4%
Previous: -339.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
37
37
37
37
37
37
38
37
37
37
38
38
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹1,053.86
-148.9% MoS
Growth-justified P/E
6.8
Growth-justified Value
₹631.6
-315.4% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
INDSWFTLAB
Small
Ind-Swift Laboratories Limited
Pharmaceuticals
match 160
34
51.5
4.0%
-16%
WATCHLIST
ARVEE
Small
Arvee Laboratories (India) Limited
Pharmaceuticals
match 157
16
57.0
7.3%
-736%
OVERVALUED
LASA
Small
Lasa Supergenerics Limited
Pharmaceuticals
match 155
5
—
-19.7%
—
OVERVALUED
INFINIUM
SME
Infinium Pharmachem Ltd.
Pharmaceuticals
match 154
36
39.1
10.5%
+16%
WATCHLIST
SAROJA
SME
Saroja Pharma Industries India Ltd.
Pharmaceuticals
match 151
48
9.8
10.1%
+77%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
NGL Fine-Chem Limited operates in API, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
76Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 81st percentile of the scored universe and 73rd percentile within Pharma. Main check: cash conversion is weak at 55/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
79 docs text-extracted · 34 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
81st percentile
overall median 67 · Pharma: 73rd pctile, median 70 · Small: 83rd pctile, median 66
Evidence depth
Financial-only
79 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
55
watch · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
82
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 72.5%.
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸3/4 latest quarters had positive YoY PAT growth.
Trust risks
- ▸2 older quarters in the 8-quarter window had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching NGL Fine-Chem Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Sep - A One to One meet has been scheduled on Wednesday, September 16, 2026 with Analyst/Investor.
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Corrigendum To The 45Th Annual Report For The Financial Year 2025-2026 20 Aug - Annual report corrigendum corrects CSR amounts from crores to lakhs; no impact on financial statements.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.